Clinical Trial

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2022-03-09; most recent amendment 2026-04-03.
Status change: Not Yet Recruiting → Recruiting 2023-04-20
Trial Details
NCT Number NCT05286788
Lead Sponsor Nationwide Children's Hospital
Collaborators: Children's Hospital Colorado
Conditions Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Enrollment 38 participants
Start Date 2023-04-10
Primary Completion 2027-04-10 (estimated)
Study Completion 2027-04-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-08